Erik Berntorp
1 – 250 of 329
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
A need to increase von Willebrand disease awareness : vwdtest.com – A global initiative to help address this gap
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
- 2021
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
(
- Contribution to journal › Article
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Haemophilia
(
- Contribution to journal › Scientific review
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Translating the success of prophylaxis in haemophilia to von Willebrand disease
(
- Contribution to journal › Scientific review
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
- 2020
-
Mark
Achieving the unimaginable : Health equity in haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease : Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
- 2019
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
(
- Contribution to journal › Scientific review
-
Mark
ROTEM and vitro reversal of warfarin with APCC
(
- Contribution to journal › Article
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
(
- Contribution to journal › Article
-
Mark
Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram : A Nordic study
(
- Contribution to journal › Article
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Coagulation factor VIII is vital for increasing global coagulation after physical exercise
(
- Contribution to journal › Article
-
Mark
Moderate haemophilia in focus
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study
(
- Contribution to journal › Article
-
Mark
A personalized approach to the management of VWD
(
- Contribution to journal › Article
-
Mark
Joint comorbidities among Swedish carriers of haemophilia : A register-based cohort study over 22 years
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Evolution of replacement therapy for von Willebrand disease : From plasma fraction to recombinant von Willebrand factor
(
- Contribution to journal › Scientific review
-
Mark
Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders : An EHA Consensus Report
(
- Contribution to journal › Article
- 2018
-
Mark
Evaluation of prophylactic therapy in haemophilia with global coagulation tests
(
- Contribution to journal › Letter
-
Mark
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis : Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
(
- Contribution to journal › Article
-
Mark
Fifth Åland Island conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
(
- Contribution to journal › Article
-
Mark
Replacement therapy during surgery in von Willebrand disease needs personalization
(
- Contribution to journal › Debate/Note/Editorial
- 2017
-
Mark
Correlation to FVIII : C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
(
- Contribution to journal › Article
-
Mark
Preference-based valuation of treatment attributes in haemophilia A using web survey
(
- Contribution to journal › Article
-
Mark
Thrombin generation assays (TGAs)
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy : The Malmö experience
(
- Contribution to journal › Article
-
Mark
Plasma-derived versus recombinant factor concentrates in PUPs : A never ending debate?
(
- Contribution to journal › Article
-
Mark
If you know you will also see : Population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The association between health utility and joint status among people with severe haemophilia A : findings from the KAPPA register
(
- Contribution to journal › Article
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
-
Mark
Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery
(
- Contribution to journal › Article
-
Mark
Low agreement between fresh and frozen-thawed platelet-rich plasma in the calibrated automated thrombogram assay
(
- Contribution to journal › Article
-
Mark
The importance of genetic factors for the development of arthropathy : A longitudinal study of children and adolescents with haemophilia A
(
- Contribution to journal › Article
-
Mark
The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
- 2016
-
Mark
ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy.
(
- Contribution to journal › Article
-
Mark
Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
2016) In Haemophilia(
- Contribution to journal › Article
-
Mark
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
(
- Contribution to journal › Article
-
Mark
Population Pharmacokinetics of Plasma-Derived Factor IX: Procedures for Dose Individualization.
(
- Contribution to journal › Article
-
Mark
Epidemiological aspects of inhibitor development in hemophilia and strategies of management
(
- Contribution to journal › Scientific review
-
Mark
Phenotype and genotype comparisons in carriers of haemophilia A
(
- Contribution to journal › Article
-
Mark
Registry-based outcome assessment in haemophilia : a scoping study to explore the available evidence
(
- Contribution to journal › Article
-
Mark
Malignancies in Swedish persons with haemophilia : a longitudinal registry study
(
- Contribution to journal › Article
-
Mark
Patients Referred for Bleeding Symptoms of Unknown Cause : Does Evaluation of Thrombin Generation Contribute to Diagnosis?
(
- Contribution to journal › Article
-
Mark
Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe
(
- Contribution to journal › Article
-
Mark
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
(
- Contribution to journal › Article
-
Mark
The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum’s disease
2016) p.657-660(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The effect of Nordic Walking on joint status, quality of life, physical ability, exercise capacity and pain in adult persons with haemophilia
(
- Contribution to journal › Article
-
Mark
Future of haemophilia outcome assessment : Registries are key to optimized treatment
(
- Contribution to journal › Article
-
Mark
Haemophilia treatment in 2030
(
- Contribution to journal › Article
- 2015
-
Mark
Effects of recombinant human prothrombin on thrombin generation in plasma from patients with haemophilia A and B.
(
- Contribution to journal › Article
-
Mark
The ageing patient with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Evaluation of Algorithms for the Treatment of Problem Bleeding Episodes in Patients With Hemophilia Having Inhibitors.
(
- Contribution to journal › Article
-
Mark
Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.
(
- Contribution to journal › Letter
-
Mark
Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?
(
- Contribution to journal › Article
-
Mark
Prophylaxis Escalation in Severe von Willebrand Disease: A Prospective Study from the von Willebrand Disease Prophylaxis Network.
(
- Contribution to journal › Article
-
Mark
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
(
- Contribution to journal › Article
-
Mark
Introduction.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inhibitors in haemophilia: what have we learned from registries? A systematic review.
(
- Contribution to journal › Scientific review
-
Mark
Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia.
(
- Contribution to journal › Article
-
Mark
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Thrombin stimulates insulin secretion via protease-activated receptor-3.
(
- Contribution to journal › Article
-
Mark
Tranexamic acid - an old drug still going strong and making a revival.
(
- Contribution to journal › Scientific review
-
Mark
Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.
(
- Contribution to journal › Scientific review
-
Mark
Interaction between VWF and FVIII in treating VWD
(
- Contribution to journal › Article
-
Mark
Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation
(
- Contribution to journal › Letter
-
Mark
Acute effects of exercise on specific and global coagulation parameters in severe haemophilia A.
(
- Contribution to journal › Letter
- 2014
-
Mark
Introduction.
(
- Contribution to journal › Article
-
Mark
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.
(
- Contribution to journal › Scientific review
-
Mark
A longitudinal study of family structure in Swedish persons with haemophilia.
(
- Contribution to journal › Article
-
Mark
Methods for individualising factor VIII dosing in prophylaxis
(
- Contribution to journal › Scientific review
-
Mark
Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding.
(
- Contribution to journal › Scientific review
-
Mark
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
(
- Contribution to journal › Letter
-
Mark
Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B.
(
- Contribution to journal › Article
-
Mark
Outcome measures in haemophilia: a systematic review
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?
(
- Contribution to journal › Article
-
Mark
Clinically relevant non-neutralizing anti-FVIII antibodies in a hemophiliac
(
- Contribution to journal › Letter
-
Mark
Textbook of hemophilia : Care of the child with hemophilia
2014) p.145-150(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2013
-
Mark
Increased burden on caregivers of having a child with haemophilia complicated by inhibitors.
2013) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
(
- Contribution to journal › Article
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
(
- Contribution to journal › Article
-
Mark
Thrombosis in patients with hemorrhagic disorders.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
(
- Contribution to journal › Article
-
Mark
History of prophylaxis.
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
-
Mark
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.
(
- Contribution to journal › Article
- 2012
-
Mark
Differences between developed and developing countries in paediatric care in haemophilia
(
- Contribution to journal › Article
-
Mark
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
(
- Contribution to journal › Article
-
Mark
Management of bleeding disorders in children
(
- Contribution to journal › Scientific review
-
Mark
Quality of life in adult patients with haemophilia - a single centre experience from Sweden.
(
- Contribution to journal › Article
-
Mark
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
2012) In Haemophilia(
- Contribution to journal › Article
-
Mark
von Willebrand's disease: a report from a meeting in the Åland islands.
(
- Contribution to journal › Article
-
Mark
Models of prophylaxis.
(
- Contribution to journal › Article
-
Mark
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(
- Contribution to journal › Article
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
(
- Contribution to journal › Article
-
Mark
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
(
- Contribution to journal › Article
-
Mark
New treatments in hemophilia: insights for the clinician.
(
- Contribution to journal › Article
-
Mark
Clinical trial design in haemophilia.
(
- Contribution to journal › Article
-
Mark
Modern haemophilia care.
(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
-
Mark
Von Willebrand disease.
2012) In Pediatric Blood & Cancer(
- Contribution to journal › Article
- 2011
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Article
-
Mark
The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
(
- Contribution to journal › Published meeting abstract
-
Mark
Bone density and health-related quality of life in adult patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Optimizing patient therapy - optimal dosing: when is enough enough?
(
- Contribution to journal › Article
-
Mark
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
(
- Contribution to journal › Article
-
Mark
Haematuria and hypertension in haemophilia - the H3 study
(
- Contribution to journal › Published meeting abstract
-
Mark
Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
(
- Contribution to journal › Article
-
Mark
Ovanliga ärftliga former av blödarsjuka. Blödningssymtom, familjehistoria och laboratorieanalyser ger diagnosen.
(
- Contribution to journal › Article
-
Mark
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Importance of rapid bleeding control in haemophilia complicated by inhibitors.
(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
-
Mark
When von Willebrand disease comes into age - A matter of change?
(
- Contribution to journal › Article
-
Mark
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
- 2010
-
Mark
Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective
(
- Contribution to journal › Article
-
Mark
Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group
(
- Contribution to journal › Published meeting abstract
-
Mark
Von Willebrand disease prophylaxis network
(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment of the critically ill patient with protein C: Is it worth the cost?
(
- Contribution to journal › Article
-
Mark
The combination of Octaplex (R) and Octanate (R) restores thrombin generation capacity in FVIII inhibitor plasma in-vitro
(
- Contribution to journal › Published meeting abstract
-
Mark
The necessity of having FVIII in VWF concentrates
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.400-400(
- Contribution to journal › Published meeting abstract
-
Mark
A retrospective study: of Octaplex (R) in the treatment of bleeding in patients with haemophilia A complicated by inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
(
- Contribution to journal › Article
-
Mark
A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.31-31(
- Contribution to journal › Published meeting abstract
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis in von Willebrand disease
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Assessment of health-related quality of life in patients with severe haemophilia with reduced bone density
(
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Network activities were initiated in December, 2009, and will extend over the next five years. von Willebrand disease prophylaxis network
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients
(
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45(
- Contribution to journal › Published meeting abstract
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
(
- Contribution to journal › Article
-
Mark
Anti-prothrombin antibodies are associated with thrombosis in children.
(
- Contribution to journal › Article
-
Mark
Von Willebrands sjukdom--från biokemi till klinisk praxis.
(
- Contribution to journal › Scientific review
-
Mark
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
(
- Contribution to journal › Article
-
Mark
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
(
- Contribution to journal › Article
- 2009
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
(
- Contribution to journal › Article
-
Mark
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Physical activity as prevention of osteoporosis in patients with severe haemophilia on long term prophylaxis
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0118-0118(
- Contribution to journal › Published meeting abstract
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Thrombin generation after emergency contraception
2009) 3rd International Symposium on Womens Health Issues in Thrombosis and Haemostasis In Thrombosis Research 123. p.152-152(
- Contribution to journal › Published meeting abstract
-
Mark
Increased thrombin generation in women with a history of preeclampsia
(
- Contribution to journal › Article
-
Mark
Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children.
(
- Contribution to journal › Article
-
Mark
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
(
- Contribution to journal › Article
-
Mark
Haemate P/Humate-P: a systematic review.
(
- Contribution to journal › Article
- 2008
-
Mark
Genetic aspects of inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.21-21(
- Contribution to journal › Published meeting abstract
-
Mark
VWD type 3 - historical review and contemporary treatment dilemmas
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful tool in the management of haemophilia A patients?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans.
(
- Contribution to journal › Article
-
Mark
Surgical evaluation of a recombinant factorVIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients
(
- Contribution to journal › Article
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
Genetic aspects and research development in haemostasis
(
- Contribution to journal › Article
-
Mark
High purity, double virus-inactivated VWF/FVIII concentrate in long term prophylaxis of von Willebrand disease - experience from prospective clinical trials and German post-licensure surveillance
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.12-12(
- Contribution to journal › Published meeting abstract
-
Mark
von Willebrand disease update: diagnostic and treatment dilemmas
(
- Contribution to journal › Article
-
Mark
Bone density in hemophilia
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.79-79(
- Contribution to journal › Published meeting abstract
-
Mark
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
Standardization and clinical utility of thrombin-generation assays.
(
- Contribution to journal › Article
-
Mark
Protecting the joints of mice and men.
(
- Contribution to journal › Article
-
Mark
Prophylaxis in von Willebrand disease.
(
- Contribution to journal › Article
-
Mark
Oestrogen treatment of constitutional tall stature in girls: is there a risk of thrombosis or bleeding?
(
- Contribution to journal › Article
-
Mark
Blödningstidsbestämning har spelat ut sin roll. Otillförlitlig metod som inte längre bör användas i rutinsjukvården
(
- Contribution to journal › Scientific review
- 2007
-
Mark
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
(
- Contribution to journal › Article
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
-
Mark
Von Willebrand: The scientist, the disease, the factor, and the treatment
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
Delays in maturation among adolescents with hemophilia and a history of inhibitors
(
- Contribution to journal › Article
-
Mark
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
Erik von Willebrand.
(
- Contribution to journal › Article
-
Mark
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
(
- Contribution to journal › Article
-
Mark
Gadolinium Contrast Agent is of Limited Value for Magnetic Resonance Imaging Assessment of Synovial Hypertrophy in Hemophiliacs.
(
- Contribution to journal › Article
-
Mark
Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate((R)) P/Humate-P((R))) in von Willebrand Disease and Haemophilia A: A Viewpoint by Eric Berntorp.
(
- Contribution to journal › Letter
-
Mark
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
(
- Contribution to journal › Article
- 2006
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Von Willebrand's disease: clinical management
(
- Contribution to journal › Article
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
(
- Contribution to journal › Article
-
Mark
Pharmacoeconomics of factor dosing in the haemophilia population.
(
- Contribution to journal › Article
-
Mark
The need for prophylaxis in von Willebrand's disease and other coagulation disorders
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept.
(
- Contribution to journal › Article
-
Mark
The von Willebrand disease prophylaxis network: exploring a treatment concept.
(
- Contribution to journal › Article
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
(
- Contribution to journal › Article
-
Mark
New Approaches to Using FEIBA in the Treatment of Inhibitor Patients.
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
The 80th anniversary of von Willebrand's disease: history, management and research
(
- Contribution to journal › Scientific review
-
Mark
The next generation of hemophilia treatment specialists
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum's disease.
2006) p.516-518(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2005
-
Mark
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
(
- Contribution to journal › Letter
-
Mark
Pharmacokinetic studies on Wilfactin((R)), a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
(
- Contribution to journal › Article
-
Mark
Cost effectiveness of haemophilia treatment: a cross-national assessment.
(
- Contribution to journal › Article
-
Mark
Risk factors for venous thrombosis in Swedish children and adolescents.
(
- Contribution to journal › Article
-
Mark
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
(
- Contribution to journal › Article
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Protein Z and protein Z-dependent protease inhibitor - Determinants of levels and risk of venous thrombosis
(
- Contribution to journal › Article
- 2004
-
Mark
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study
(
- Contribution to journal › Article
-
Mark
Economic evaluation: what are we looking for and how do we get there?
(
- Contribution to journal › Article
-
Mark
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia
(
- Contribution to journal › Article
-
Mark
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities
(
- Contribution to journal › Article
-
Mark
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden.
(
- Contribution to journal › Article
-
Mark
Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.
(
- Contribution to journal › Article
- 2003
-
Mark
The pharmacokinetics of clotting factor therapy.
(
- Contribution to journal › Article